Bruker (BRKR)

• Market cap: $8.64B
• 1 day: 3.09%
• 5 days: 0.56%
• 1 month: 6.80%
• 3 months: -15.61%
• 6 months: -14.34%
• Year to date: -21.16%
• 1 year: -21.66%
• 5 years: 10.44%
• 10 years: 190.22%
• Sector: Industrials
• Industry: Laboratory Analytical Instruments

About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from Asia Pacific.

Employees: 9,707

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

67% more funds holding in top 10

Funds holding in top 10: 3 [Q2] → 5 (+2) [Q3]

29% more repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 117

7% more capital invested

Capital invested by funds: $7.43B [Q2] → $7.93B (+$506M) [Q3]

0% more funds holding

Funds holding: 362 [Q2] → 362 (+0) [Q3]

0% more first-time investments, than exits

New positions opened: 63 | Existing positions closed: 63

0.22% less ownership

Funds ownership: 77.02% [Q2] → 76.8% (-0.22%) [Q3]

14% less call options, than puts

Call options by funds: $2.35M | Put options by funds: $2.74M

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $60 5% upside
• Avg. target: $71 24% upside
• High target: $80 40% upside

8 analyst ratings

• positive: 5 63%
• neutral: 3 38%
• negative: 0 0%

Guggenheim Subbu Nambi 50% 1-year accuracy 4 / 8 met price target	26% upside $72	Buy Initiated	19 Dec 2024
B of A Securities Derik De Bruin 32% 1-year accuracy 6 / 19 met price target	40% upside $80	Buy Maintained	13 Dec 2024
UBS Dan Leonard 29% 1-year accuracy 2 / 7 met price target	16% upside $66	Neutral Assumed	10 Dec 2024
Goldman Sachs Matthew Sykes 64% 1-year accuracy 29 / 45 met price target	5% upside $60	Neutral Upgraded	5 Dec 2024
Citigroup Patrick Donnelly 43% 1-year accuracy 13 / 30 met price target	32% upside $75	Buy Maintained	6 Nov 2024